0      0

AM23-SN-29-O - AM23-SN-29-O: The Approach to Bleeding in Patients Receiving Targeted Factor XI Therapy (Enduring)

Expiration Date: Dec 31, 2025

Credits: None available.

The ideal goal of anticoagulant therapy is to attenuate thrombosis without compromising hemostasis. Although newer oral anticoagulants such as apixaban, rivaroxaban, and edoxaban are associated with less intracranial hemorrhage than vitamin K antagonists, bleeding remains their major side effect. Because of the decreased bleeding risk associated with targeting Factor XI, there has been a tremendous interest in developing agents to inhibit Factor XI activity or to attenuate Factor XI levels. This session will review the role of Factor XI in the development of thrombosis and review current approaches in inhibiting or decreasing Factor XI activity. Results from animal models and recent clinical trials of FXIa inhibition will be presented. As a potentially new anticoagulant, approaches to the diagnosis and management when associated with bleeding will be discussed. These approaches will be discussed in the context of bleeding patients with congenital and acquired Factor XI deficiency.

Learning Objectives:

  • Describe the role of Factor XI in coagulation and thrombosis
  • Understand the various mechanisms of action of potential agents that inhibit Factor XI activity and expression
  • 3. Describe results from recent clinical studies targeting Factor XI as an anti-thrombotic agent
  • Develop approaches for the management of bleeding in patients who are undergoing treatments that target Factor XI activity or expression




  • David Gailani, MD:
    Anthos Therapeutics: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Aronora: Consultant/Advisory Board (Ongoing); Bristol-Myers Squibb: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Ionis: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Janssen Pharmaceuticals: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing)
  • Ophira Salomon, MD:
    No financial relationships to disclose
  • Edward Wong, MD:
    Quest Diagnostics: Stock Shareholder (self-managed) (Ongoing)

All relevant financial relationships have been mitigated.

By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available

AM23-SN-29-O: The Approach to Bleeding in Patients Receiving Targeted Factor XI Therapy (Enduring) Evaluation